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Patients with more comorbidities have
better detection of chronic conditions, but
poorer management and control: findings
from six middle-income countries
Grace Sum1*, Gerald Choon-Huat Koh1, Stewart W. Mercer2, Lim Yee Wei3, Azeem Majeed4, Brian Oldenburg5 and
John Tayu Lee1,4,5
Abstract
Background: The burden of non-communicable diseases (NCDs) is rising rapidly in middle-income countries (MICs),
where NCDs are often undiagnosed, untreated and uncontrolled. How comorbidity impacts diagnosis, treatment,
and control of NCDs is an emerging area of research inquiry and have important clinical implications as highlighted
in the recent National Institute for Health and Care Excellence guidelines for treating patients suffering from
multiple NCDs. This is the first study to examine the association between increasing numbers of comorbidities with
being undiagnosed, untreated, and uncontrolled for NCDs, in 6 large MICs.
Methods: Cross-sectional analysis of the World Health Organisation Study of Global Ageing and Adult Health (WHO
SAGE) Wave 1 (2007–10), which consisted of adults aged ≥18 years from 6 populous MICs, including China, Ghana,
India, Mexico, Russia and South Africa (overall n = 41, 557).
Results: A higher number of comorbidities was associated with better odds of diagnosis for hypertension, angina,
and arthritis, and higher odds of having treatment for hypertension and angina. However, more comorbidities were
associated with increased odds of uncontrolled hypertension, angina, arthritis, and asthma. Comorbidity with
concordant conditions was associated with improved diagnosis and treatment of hypertension and angina.
Conclusion: Patients with more comorbidities have better diagnosis of chronic conditions, but this does not
translate into better management and control of these conditions. Patients with multiple NCDs are high users of
health services and are at an increased risk of adverse health outcomes. Hence, improving their access to care is a
priority for healthcare systems.
Keywords: Comorbidity, Non-communicable diseases, Chronic conditions, Ageing, Health monitoring, Access to
care
What we know now and knowledge gaps
 The burden of non-communicable diseases (NCDs)
is rising rapidly in middle-income countries (MICs),
where NCDs are often undiagnosed, untreated and
uncontrolled.
 From the limited number of studies in high-income
countries, there is preliminary evidence that more
comorbidities negatively impact treatment and con-
trol of NCDs. There are also mixed results on how
concordant and discordant comorbidities influence
treatment and control.
 There is a specific knowledge gap in MICs on how
more comorbidities with a NCD is associated with
the diagnosis, treatment, and control of the NCD.
 There is also a knowledge gap in MICs on how
concordant and discordant comorbidities with a
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NCD are associated with the diagnosis, treatment,
and control of the NCD.
What this study adds
 A higher number of comorbidities was associated
with better diagnosis of some NCDs.
 However, this did not translate into better management
and control of NCDs. More comorbidities associated
with even worse control of NCDs.
 Comorbidity with concordant conditions was
associated with improved diagnosis and treatment,
compared to comorbidity with discordant
conditions.
 Patients with more comorbidities have better
diagnosis of chronic conditions, but this does not
translate into better management and control of these
conditions. Patients with multiple NCDs are high
users of health services and are at an increased risk of
adverse health outcomes. Hence, improving their
access to care is a priority for healthcare systems.
Background
Non-communicable diseases (NCDs) are the leading
cause of global disease burden with 85% of premature
mortality due to NCDs occurring in low- and-middle in-
come countries [1]. In middle-income countries (MICs),
there is a high prevalence of multiple chronic conditions
in young adults, and not only in the elderly [2]. Poor
chronic disease outcomes in MICs pose a major hurdle
to attain the health target 3.4 of United Nation’s Sustain-
able Development Goals, which is to reduce premature
mortality from NCDs by a third by 2030 [3].
How comorbidity, defined as the presence of co-
occurring NCDs in an individual [4, 5], impacts diagnosis,
treatment, and control of NCDs is an emerging area of re-
search inquiry and has important clinical implications as
highlighted in the recent National Institute for Health and
Care Excellence guidelines for treating patients suffering
from multiple NCDs [6]. A small number of studies in
high-income countries show mixed results on the implica-
tions of comorbidities on the management and control of
single NCDs, such as hypertension or diabetes [7–10]. A
study in the United States revealed that the proportion of
persons with uncontrolled hypertension increased as the
number of unrelated comorbid NCDs increased [9].
In contrast to this finding, a recent ecological study in
the United Kingdom found that unrelated and related co-
occurring NCDs could either be associated with better or
worse treatment outcomes for patients with diabetes [8].
To the best of our knowledge, there are very few studies
on this topic in MICs, and there is a need to fill the gap
on comorbidities in MICs [11]. Findings from the small
number of studies in high-income countries may not be
applicable to MICs, as their health systems vary substan-
tially and patients in MICs tend to have less frequent visits
with well-trained healthcare providers [2, 12].
This study aims to examine how more comorbidities is
associated with being undiagnosed, untreated, and uncon-
trolled for NCDs in 6 high-population MICs. We also in-
vestigate the odds of NCDs being undiagnosed, untreated,
and uncontrolled, when comorbidities are concordant ver-
sus discordant. This paper considers the implications of the
research findings for clinicians and policymakers on the re-
vision of health structures and policies to improve manage-
ment and control of NCDs in the context of MICs.
Methods
Sample and data
We used cross-sectional data from the World Health
Organisation Study of Global Ageing and Adult Health
(WHO SAGE) Wave 1 (2007–10) which collected na-
tionally representative samples of people aged 50+ years
in China, Ghana, India, Mexico, Russia and South Africa,
with a smaller sample of adults aged 18–49 years in each
country for comparison [13]. SAGE contains information
on sociodemographic characteristics, anthropometrics
and biomarkers, NCDs, healthcare utilisation, quality of
life and well-being, social cohesion, and impact on care-
giving [13]. Face-to-face interviews were conducted in
all countries, using a combination of computer-assisted
personal interview, and paper and pencil [13].
The original total sample size of adults aged ≥18 years
was 44,089 (China: 15,009, India: 12,198, Ghana: 5563,
Russia: 4350, Mexico: 2744, South Africa: 4225). We ex-
cluded those who had missing values on outcome vari-
ables and covariates (5.7% of entire sample). Final sample
size was 41,557 (China: 14,906, India: 11,159, Ghana:
5067, Russia: 4330, Mexico: 2618, South Africa: 3477).
Variables
Figure 4 in Appendix summarises predicting variables
and outcomes.
Chronic conditions
SAGE collected information on 9 NCDs including
hypertension, angina, arthritis, asthma, chronic lung dis-
ease (CLD), diabetes, cataract, stroke, and depression.
All 9 NCDs had questions on self-reported diagnosis
and treatment. Subjects self-reported the NCD if they
answered affirmatively to: “Have you ever been diag-
nosed with …? ”. Subjects self-reported being treated for
the NCD if they answered affirmatively to: “Have you
been taking medication or other treatment for it during
the ( … last 2 weeks / … last 12 months)?”
SAGE had symptom-based assessment or physical mea-
surements for only 6 of 9 NCDs. Hence only these 6 of 9
NCDs could be assessed in this study for being
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undiagnosed, or for being uncontrolled. These were hyper-
tension, angina, arthritis, asthma, CLD, and depression.
For hypertension, physical measurement of blood pressure
was taken, and subjects with hypertension had systolic blood
pressure ≥ 140mmHg or diastolic blood pressure ≥ 90
mmHg [14]. For angina, depression, arthritis, asthma, and
CLD, symptom-based assessments were according to vali-
dated symptom scales derived through a standard algorithm
based on a set of symptomatic questions from SAGE survey
(i.e. Rose questionnaire for angina [15, 16], Composite Inter-
national Diagnostic Interview for depression [17, 18], re-
ceiver operating characteristic curve analysis that generated
an algorithm for arthritis diagnosis by symptoms [19]).
These methods were consistent with SAGE individual coun-
try reports published by WHO [20, 21]. Table 3 in Appendix
shows details on the symptom-based assessment.
Table 1 Sample characteristics of the population of China, India, Ghana, Russia, Mexico, and South Africa
China India Ghana Russia Mexico South Africa Pooled
Total (N) 14,906 11,159 5,067 4,330 2,618 3,477 41,557
Sex (%)
Male 46.7 38.74 52.65 35.64 38.20 39.72 43.01
Female 53.3 61.26 47.35 64.36 61.80 60.28 56.99
Marital Status (%)
Not married 16.75 22.34 41.70 46.26 41.29 55.88 29.19
Married 83.25 77.66 58.30 53.74 58.71 44.12 70.81
Age Group (%)
18-29 1.44 14.27 2.53 2.26 2.18 2.04 5.20
30-39 3.41 14.75 5.94 3.39 6.49 2.59 6.89
40-49 6.05 12.54 7.20 3.95 7.30 3.36 7.57
50-59 38.70 26.16 33.04 33.76 16.23 40.47 32.86
60-69 26.46 19.92 23.60 24.57 34.91 29.59 24.95
70+ 23.94 12.37 27.69 32.06 32.89 21.94 22.53
Multimorbidity (%)
0 NCDs 61.68 74.75 56.80 50.21 68.43 48.33 64.00
1 NCD 24.47 10.47 26.02 11.13 14.76 33.95 17.00
2 or more NCDs 13.85 14.78 17.18 38.66 16.81 17.72 19.00
Mean number of NCDs 1.03 1.41 1.23 1.88 1.36 1.40 1.11
Education Level (%)
No schooling 23.93 45.18 50.74 0.95 17.07 24.04 30.09
Primary or lower 35.66 25.79 23.03 9.01 59.43 47.66 31.20
Secondary 21.27 12.47 5.51 18.15 10.62 14.75 15.44
Tertiary or higher 19.14 16.55 20.72 71.89 12.87 13.55 23.27
Wealth Quintile (%)
Q1 (lowest) 19.03 17.85 19.44 17.78 20.59 20.13 18.82
Q2 19.82 19.23 19.62 19.40 20.55 20.19 19.67
Q3 20.01 19.14 19.76 19.98 18.56 19.64 19.62
Q4 20.66 21.02 20.70 20.35 20.66 20.07 20.68
Q5 (highest) 20.48 22.75 20.49 22.49 19.63 19.96 21.20
Location (%)
Rural 50.87 74.53 59.05 24.32 26.70 33.62 52.49
Urban 49.13 25.47 40.95 75.68 73.30 66.38 47.51
Insurance (%)
No insurance 12.97 95.91 63.77 0.48 No data 82.17 48.14
With insurance (mandatory/voluntary) 87.03 4.09 36.23 99.52 No data 17.83 51.86
NCD Non-communicable disease, N Sample size, Q Quintile
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Predicting variables
The first predicting variable was number of comorbidities.
Subjects were categorised by number of diagnosed comor-
bidities: 0, 1, 2, 3 and 4+ comorbidities. The second pre-
dicting variable was co-occurrence of each NCD with only
concordant NCDs, only discordant NCDs, and only de-
pression. Concordant NCDs were those that represented
parts of the same overall pathophysiologic risk profile [7].
For example, studies considered diabetes and hyperten-
sion “concordant” due to similar pathophysiologic risk
profiles or were more likely the focus of a similar disease
complex and management plan [7, 22]. Conditions con-
sidered “discordant” were not directly related in pathogen-
esis or did not share an underlying predisposing factor [9].
For example, asthma and arthritis are considered “discord-
ant” to diabetes and hypertension [9]. For our study, con-
cordant sets of NCDs included (i) hypertension, angina,
stroke, diabetes [9, 22]; (ii) diabetes, cataract [23]; (iii)
asthma, CLD [24]. Two NCDs, arthritis and depression,
did not have any concordant NCDs.
Outcomes
Firstly, we examined the associations between being un-
diagnosed, untreated, and uncontrolled for NCDs with
increasing comorbidity, and secondly, the associations
between being undiagnosed, untreated and uncontrolled
for NCDs when the NCD co-occurs with only concord-
ant NCDs, only discordant NCDs, and only depression.
Undiagnosed subjects did not have self-reported diag-
nosis of the NCD by a medical professional but had the
NCD based on SAGE assessment. Untreated subjects
self-reported previous diagnosis of the NCD by a med-
ical professional but self-reported not having treatment
(medications, lifestyle changes, therapy, and/or counsel-
ling). Subjects who did not have treatment in the last 2
weeks and in the last 12 months were referred to in this
study as (‘unT-last 2 weeks’) and (‘unT-last 12 months’),
respectively. Uncontrolled subjects self-reported being
both diagnosed and treated for the NCD, but had symp-
toms of the NCD based on SAGE assessment. Uncon-
trolled subjects who had treatment in the last 2 weeks
were referred to as ‘unC-T-last 2 weeks’ and those who
had treatment in the last 12 months were referred to as
‘unC-T-last 12 months’. Figure 5 and Table 4 in Appen-
dix describe the detailed definitions of being undiag-
nosed, untreated, and uncontrolled.
Covariates
Covariates were age (18-49 years, 50-64 years, 65 +
years), sex, marital status (married, not married), educa-
tion (primary or less, secondary, tertiary and above),
wealth quintiles, residence (rural, urban), and health in-
surance (with/without insurance).
Statistical analysis
We summarised subject characteristics by country with
pooled data. For each NCD, we examined the prevalence
of subjects with 0, 1, 2, 3, and 4+ comorbid conditions.
For the 6 NCDs that had symptom-based assessment, we
presented the prevalence of undiagnosed subjects as their
number of comorbidities increased from 0 to 1, 2, 3, and
4+. For all 9 NCDs, we presented prevalence of untreated
subjects as the number of comorbidities increased from 0
to 1, 2, 3, and 4+. For the 6 NCDs that had symptom-based
assessment, we presented the prevalence of uncontrolled
subjects as the number of comorbidities increased from 0
to 1, 2, 3, and 4+. In addition, we presented the prevalence
of being undiagnosed, untreated, and uncontrolled when
each NCD co-occurred with only concordant NCDs, only
discordant NCDs, and only depression.
Table 2 Prevalence of undiagnosed, untreated, and uncontrolled subjects for each non-communicable disease
Non-communicable disease (%)
Hypertension
(n= 9778)
Angina
(n= 3274)
Arthritis
(n= 540)
Asthma
(n=
153)
Chronic Lung
Disease
(n= 2455)
Diabetes
(n= 2735)
Cataracta
(n= 3739)
Depression
(n= 1129)
Stroke
(n= 1205)
Prevalence
of subjects
(%)
1. Undiagnosed 59.11 62.23 42.76 55.48 50.27 NA NA 67.57 NA
2a. unT-last 2 weeks
(untreated in the last
2 weeks)
34.89 42.04 58.39 46.21 91.19 33.76 NA 70.45 57.66
2b. unT-last 12 months
(untreated in the last
12 months)
17.43 18.11 31.74 27.84 84.84 24.48 59.98 63.54 42.47
3a. unC-T-last 2 weeks
(treated in the last 2
weeks, and uncontrolled)
71.14 83.61 77.41 78.00 81.72 NA NA 50.34 NA
3b. unC-T-last 12 months
(treated in the last 12
months, and uncontrolled)
66.82 77.77 72.81 77.89 70.05 NA NA 62.21 NA
aAssessed untreated in the last 5 years
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Fig. 1 (See legend on next page.)
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We conducted a series of multivariable logistic regression
analyses. For each NCD, we obtained adjusted odds ratios
(AORs) of being undiagnosed, untreated and uncontrolled:
Firstly, in association with greater number of comorbidities,
and secondly, in association with the co-occurrence of only
concordant NCDs, versus only discordant NCDs, and ver-
sus only depression. We adjusted for country fixed effects
and covariates in all the regression models. The data ana-
lyses were weighted to account for the complex, multi-
stage design of the SAGE survey. We performed statistical
analyses using Stata 15∙1(StataCorp).
Results
Sample characteristics
We presented subjects’ characteristics by country in Table 1.
Median age was 58 (IQR = 51–68) years. The prevalence of
subjects with 2 or more NCDs was overall 19%, and was
38.7% in Russia, 17.7% in South Africa, 17.2% in Ghana,
16.8% in Mexico, 14.8% in India, and 13.9% in China. Using
pooled data, 43.0% were male, 22.5% were aged above 70
years, 61.3% had primary school education or less, 18.8%
were from the lowest income quintile, 52.5% resided in
rural areas, and 48.1% did not have insurance. Table 5 in
Appendix displays the prevalence of subjects with 0, 1, 2, 3,
and 4+ comorbidities for each NCD.
Undiagnosed NCDs
Table 2 shows the prevalence of subjects undiagnosed
for each NCD, which ranged from 42.8% for undiag-
nosed arthritis to 62.2% for undiagnosed angina.
More comorbidities were associated with decreased
odds of undiagnosed hypertension, angina and arthritis,
but not for asthma, CLD, and depression (Fig. 1a). Comor-
bidity with concordant conditions was associated with de-
creased odds of undiagnosed hypertension and angina, but
not for arthritis, asthma, CLD, and depression (Fig. 1b).
Untreated NCDs
Table 2 shows the prevalence of subjects untreated for
each NCD, with highest prevalence for CLD (91.2%
‘unT-last 2 weeks’, 84.8% ‘unT-last 12 months’), and low-
est prevalence for diabetes (33.8% ‘unT-last 2 weeks’)
and hypertension (17.4% ‘unT-last 12 months’).
More comorbidities were associated with decreased
odds of untreated hypertension and angina, but not arth-
ritis, asthma, CLD, diabetes, depression and stroke for
‘unT-last 12months’ (Fig. 2a). Similar results were seen
for untreated hypertension and angina for ‘unT-last 2
weeks’ (Figure 6a in Appendix). In contrast, comorbidity
was associated with increased odds of untreated diabetes.
Comorbidity with concordant conditions was associ-
ated with decreased odds of untreated hypertension and
angina, but not arthritis, asthma, CLD, diabetes, depres-
sion and stroke (Fig. 2b, Figure 6b in Appendix).
Uncontrolled NCDs
Table 2 shows the prevalence of subjects uncontrolled
for each NCD, with highest prevalence for angina (83.6%
‘unC-T-last 2 weeks’; 77.8% ‘unC-T-last 12 months’), and
lowest prevalence for depression (50.3% ‘unC-T-last 2
weeks’; 62.2% ‘unC-T-last 12 months’).
More comorbidities were associated with increased
odds of uncontrolled hypertension, angina, arthritis, and
asthma, but not CLD and depression for ‘unC-T-last 12
months’ (Fig. 3a). Similar results were seen for ‘unC-T-
last 2 weeks’ (Figure 7a in Appendix).
Comorbidity with concordant conditions was not asso-
ciated with decreased nor increased odds of being un-
controlled for all NCDs (Fig. 3b, Figure 7b in Appendix).
Tables 6-15 in Appendix show prevalence of being un-
diagnosed, untreated and uncontrolled for each NCD, in
association with greater comorbidity, and with having
only concordant NCDs, only discordant NCDs, and only
depression.
Discussion
Principal findings
More comorbidities were associated with better diagno-
sis of hypertension, angina and arthritis, and better odds
of having treatment for hypertension and angina. How-
ever, more comorbidities were associated with worse
control of hypertension, angina, arthritis, and asthma.
Comorbidity with concordant conditions was associ-
ated with decreased odds of undiagnosed and untreated
hypertension and angina. Comorbidity with concordant
conditions was not associated with decreased nor in-
creased odds of being uncontrolled for NCDs.
Previous literature
Our finding on the positive effect of comorbidities on diag-
nosis is consistent with the small number of existing arti-
cles. Subjects with more comorbidities likely resulted in
(See figure on previous page.)
Fig. 1 a Odds of being undiagnosed for each non-communicable disease (NCD), with increasing comorbidity. +Multivariable logistic regression
adjusted for age, sex, marital status, education level, income level, residence, insurance, and country fixed effects. b Odds of being undiagnosed
for each non-communicable disease (NCD), with only concordant NCDs, only discordant NCDs, and only depression. +Multivariable logistic
regression adjusted for age, sex, marital status, education level, income level, residence, insurance, and country fixed effects. ^Concordant NCDs:
(a) hypertension, angina, diabetes, stroke; (b) asthma, chronic lung disease
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more frequent visits to, and interactions with multiple
health providers. Healthcare professionals were more likely
to detect previously undiagnosed co-occurring conditions
[25, 26], such as hypertension, angina, and arthritis in this
particular study. More comorbidities and increased fre-
quency of healthcare visits were likely associated with a
greater tendency for routinely taken blood pressure mea-
surements to indicate hypertension, and for patients to self-
report “chest pains” and arthritis symptoms [27–29]. For
other conditions such as CLD and depression that require
non-routine checks and are less self-reported, they may still
be undiagnosed despite more patients having more comor-
bidities and more frequent healthcare visits [30–33].
Our finding on more comorbidities being associated with
decreased odds of untreated hypertension and angina was
not consistent with the small amount of existing literature,
which mostly showed that comorbidity was associated with
increased odds of untreated conditions. Existing studies
showed that patients had difficulty coping with complex
treatment regiments from polypharmacy, and had poor ad-
herence from adverse drug events and high out-of-pocket
expenditures on medicines [6, 34–36]. The difference in
our findings and current literature is likely explained by our
study examining only whether subjects were taking treat-
ment or not, and did not assess if treatment was adequate,
in terms of adherence to medicines (i.e. dose, frequency,
duration, administration (e.g. techniques for subcutaneous
insulin injections or inhaler use), route (oral, parenteral)),
and to lifestyle modifications [37]. Our study showed that
with more comorbidities, subjects had higher odds of taking
treatment, but we expect that in reality, with more comor-
bidities, odds of treatment adherence and having adequate
treatment would decline.
Our finding on more comorbidities being associated
with poorer control is also consistent with the little
amount of existing literature. The difficulty controlling
NCDs tend to be exacerbated with more co-occurring
conditions, and patients with comorbidities were less
likely to have certain NCDs addressed [7, 9, 10]. Our
study also showed that concordant comorbidities were
associated with decreased odds of both undiagnosed and
untreated hypertension and angina. Previously undiag-
nosed concordant NCDs may have a higher tendency to
be simultaneously diagnosed during consultations with
physicians for the primary NCD of interest, and
concordant NCDs are more likely to have better co-
ordination of care [6, 9, 38].
Our study’s finding that discordant conditions were not
associated with poorer control of NCDs is generally in
contrast to the literature. The small number of existing
studies have revealed that discordant comorbidities, which
have different pathophysiology and management plans,
compromise the quality of care of the patient [7, 9, 39].
For example, a study in the United States on hypertension
found that patients with discordant conditions were less
likely to have controlled hypertension [9]. The existing lit-
erature is from high-income countries with likely higher
adherence to treatment [40–42], and in contrast, adher-
ence to treatment may be lower in MICs due to financial
constraints and lower health literacy [36, 43]. Hence this
non-adherence in MICs may explain the lack of difference
between concordant versus discordant comorbidities in
the association with control of NCDs.
Strengths and limitations
This is the first study on high-population MICs that in-
vestigates the associations between comorbidity and the
odds of being undiagnosed, untreated, and uncontrolled
for NCDs. Self-reported diagnosis of NCDs may be
under-reported and symptom-based assessment of
NCDs may not correlate with true medical status [13,
44, 45]. Additionally, stigma could be a reason for
under-reporting of depression in MICs [32, 46]. These
limitations may have implications on under-estimations
of associations in the study. However, previous work
suggests this may not be a substantial problem as SAGE
incorporated measures to minimise these issues [45].
There may be differential survey responses across coun-
tries. However, the survey methodology included strat-
egies to detect and correct for systematic reporting
biases in health interview surveys, such as vignette
methods and objective performance tests [44]. Strategies
were used to improve data comparability, such as utilis-
ing common definitions of concepts, common data col-
lection methods and translations, rigorous sample
design, and post-hoc harmonisation [44].
Additionally, this survey only asked if subjects were tak-
ing treatment (medicines, lifestyle changes), but did not
measure self-reported treatment adherence (i.e. dosage,
(See figure on previous page.)
Fig. 2 a Adjusted odds ratios of being untreated in the last 12 months (unT-last 12 months) for each non-communicable disease (NCD), with
increasing comorbidity. +Multivariable logistic regression adjusted for age, sex, marital status, education level, income level, residence, insurance,
and country fixed effects. Note: Cataract was only assessed for being untreated in the last 5 years. b Odds of being untreated in the last 12
months (unT-last 12 months) for each non-communicable disease (NCD), with only concordant NCDs, only discordant NCDs, and only depression.
+Multivariable logistic regression adjusted for age, sex, marital status, education level, income level, residence, insurance, and country fixed
effects^Concordant NCDs: (a) hypertension, angina, diabetes, stroke; (b) diabetes, cataract; (c) asthma, chronic lung disease. Note: Cataract was
only assessed for being untreated in the last 5 years.
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frequency, duration, etc) [37]. There are limitations of the
Rose questionnaire for assessing angina, including it being
short in length, and that subjects with mental health disor-
ders may be more likely to have false positive results [47].
However, large cohort studies showed that the Rose ques-
tionnaire had good predictive ability, and false positives
from individuals with mental health conditions may be
minimal [47–50]. This study did not adjust for the number
of visits to a general practitioner in clinics to avoid possible
over-adjustment bias. The associations between more co-
morbidities with better detection of previously undiagnosed
NCDs [51], could be mediated by more clinic visits and in-
teractions with healthcare professionals from having more
comorbidities [12, 25, 26, 52]. The study was based on 9
NCDs, so future work could examine more conditions. For
example, a large-scale Scotland study included 40 NCDs
[53]. The study’s cross-sectional design does not allow for
causal interpretations, and studies that use prospective co-
hort designs could examine how comorbidities cause treat-
ment and control of NCDs in subjects that are followed-up
prospectively, such as over a few years [6].
Clinical and policy implications
Our study revealed that subjects with more comorbidity had
better detection of NCDs, but control was worse with more
comorbidity. There are three principle possible explanations.
First, it may be related to poor access to care, whereby pa-
tients with multiple chronic conditions are getting treatment
for their conditions (perhaps from a pharmacy) but there is
a lack of access to care from the primary care system [54–
57]. It could also relate to cost, such as a lack of comprehen-
sive universal coverage fee at the point of care [36, 58–60].
Second, it could be from suboptimal adherence to medica-
tions [59, 60]. It is well documented that adherence drops as
polypharmacy rises [34, 36, 61]. The lack of intentional on-
going monitoring by physicians and allied health profes-
sionals might compound this problem, as regular follow-up
could include checks on adherence and reinforce the im-
portance of taking the prescribed medications. Third, it
could be due to a lack of effectiveness of medication pre-
scribed for each condition in patients with multiple chronic
conditions [62]. For most treatments of individual NCDs,
the evidence is based on randomised controlled trials which
exclude patients with multiple NCDs [62–64]. Thus what
works in a patient with a single condition, may not work in
a patient with the same NCD with comorbidities [65].
In reality, the problem may be a combination of these
three possibilities. Primary healthcare clinicians need to
improve the follow up on patients, in order to assess pos-
sible discontinuation of certain treatments due to adverse
drug events, and the financial constraints that limit pa-
tients’ ability to go for follow up check-ups and refilling
prescriptions [36, 56, 57]. Another clinical implication is
on prioritising NCDs, whereby clinicians should assess
NCD profiles of patients, prioritise treatment for patients
who would have the greatest clinical benefit of better
management and control, and consider personal prefer-
ences of patients for managing various NCDs [6, 66–68].
Policies could prioritise NCDs that have higher prevalence
or burden, such as focusing on lowering out-of-pocket ex-
penditures for follow-up visits to healthcare providers and
medicines [36, 69]. Policies also need to address continual ac-
cessibility to healthcare after first diagnosis. In MICs, it is not
uncommon for patients to travel from rural residences to the
urban areas to seek medical treatment, limiting their ability
to regularly visit healthcare services and continue treatment,
which results in suboptimal control of NCDs [52, 70, 71]. In
addition, there are complexities of insurance policies. Health
insurance from employers may be limited to certain districts
or urban areas in MICs, and it is possible that healthcare for
different conditions are covered by health providers in differ-
ent physical locations [72, 73]. This problem aggravates the
already existing fragmentation of care from utilising multiple
health providers and services [53, 74].
Fragmented healthcare is a challenge for patients, policy-
makers, and clinicians. Reorganising healthcare structures
particularly primary care, would benefit individuals with
multiple chronic conditions who often have difficulty man-
aging treatment due to polypharmacy, have multiple health
providers and medical appointments, high financial burden,
and suboptimal control of conditions [6, 11, 53, 74].
Conclusion
Patients with multiple chronic conditions may have better
detection of some chronic conditions, but this does not
translate into better management of these conditions. As
these patients are high users of health services and are at
increased risk of adverse health outcomes, improving their
access to care is a priority for health systems. Clinical
guidelines should move away from the current focus on
single diseases and be tailored to better suit the needs of
patients with multiple chronic conditions.
(See figure on previous page.)
Fig. 3 a Odds of being uncontrolled (unC-T-last 12 months) for each non-communicable disease (NCD), with increasing comorbidity.
+Multivariable logistic regression adjusted for age, sex, marital status, education level, income level, residence, insurance, and country fixed effects.
b Odds of being uncontrolled (unC-T-last 12 months) for each non-communicable disease (NCD), with only concordant NCDs, only discordant
NCDs, and only depression. +Multivariable logistic regression adjusted for age, sex, marital status, education level, income level, residence,
insurance, and country fixed effects. ^Concordant NCDs: (a) hypertension, angina, diabetes, stroke; (b) diabetes, cataract; (c) asthma, chronic
lung disease
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Appendix
Fig. 4 Predicting and outcome variables
Fig. 5 Classification of subjects who are undiagnosed, untreated, and uncontrolled
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Fig. 6 (See legend on next page.)
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(See figure on previous page.)
Fig. 6 a Adjusted odds ratios of being untreated in the last 2 weeks (unT-last 2weeks) for each non-communicable disease (NCD), with increasing
comorbidity. +Multivariable logistic regression adjusted for age, sex, marital status, education level, income level, residence, insurance, and country
fixed effects. Note: Cataract was only assessed for being untreated in the last 5 years (see Figure 6a). b Odds of being untreated in the last 2
weeks (unT-last 2weeks) for each non-communicable disease (NCD), with only concordant NCDs, only discordant NCDs, and only depression.
+Multivariable logistic regression adjusted for age, sex, marital status, education level, income level, residence, insurance, and country fixed effects.
^Concordant NCDs: (a) hypertension, angina, diabetes, stroke; (b) diabetes, cataract; (c) asthma, chronic lung disease. Note: Cataract was only
assessed for being untreated in the last 5 years (see Figure 6b)
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Fig. 7 (See legend on next page.)
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Fig. 7 a Odds of being uncontrolled (unC-T-last 2weeks) for each non-communicable disease (NCD), with increasing comorbidity. +Multivariable
logistic regression adjusted for age, sex, marital status, education level, income level, residence, insurance, and country fixed effects. b Odds of be-
ing uncontrolled (unC-T-last 2weeks) for each non-communicable disease (NCD), with only concordant NCDs, only discordant NCDs, and only de-
pression. +Multivariable logistic regression adjusted for age, sex, marital status, education level, income level, residence, insurance, and country
fixed effects. ^Concordant NCDs: (a) hypertension, angina, diabetes, stroke; (b) diabetes, cataract; (c) asthma, chronic lung disease
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Table 3 Algorithms used to ascertain presence of non-communicable diseases
NCDs Self-reported diagnosis Physical measurement/Symptom-based
assessment
Algorithm for physical
measurement/symptom-based
assessment
Hypertension Have you ever been diagnosed with high
blood pressure?
Take average of three blood pressure readings.
High blood pressure is defined as systolic blood
pressure≥140mmHg and diastolic blood pressure
≥90mmHg.
High blood pressure is defined as
systolic blood pressure≥140mmHg
and diastolic blood pressure
≥90mmHg.
Stroke Have you ever been told by a health
professional that you have had a stroke
No symptom-based assessment No symptom-based assessment
Diabetes Have you ever been diagnosed with
diabetes?
No symptom-based assessment No symptom-based assessment
Cataract In the last 5 years, were you diagnosed
with a cataract in one or both of your eyes?
No symptom-based assessment No symptom-based assessment
Arthritis Have you ever been diagnosed with/told
you have arthritis (a disease of the joints, or
by other names rheumatism or
osteoarthritis)?
Qn 1: During the last 12 months, have you
experienced pain, aching, stiffness or swelling in
or around the joints (like arms, hands, legs or
feet) which were not related to an injury and
lasted for more than a month?
a. Yes
b. No
Qn 2: During the last 12 months, have you
experienced stiffness in the joint in the morning
after getting up from bed, or after a long rest of
the joint without movement?
a. Yes
b. No
Qn 3: How long did the stiffness last?
a. about 30mins or less
b. more than 30 mins
Qn 4: Did this stiffness go away after exercise or
movement in the joint?
a. Yes
b. No
Arthritis=
Option ‘a’ to both question 1 and
question 2.
OR
Option ‘a’ to both question 3 and
question 4.
Angina Have you ever been diagnosed with angina
or angina pectoris?
Qn 1: During the last 12 months, have you
experienced any pain or discomfort in your chest
when you walk uphill or hurry?
a. Yes
b. No
Qn 2: During the last 12 months, have you
experienced any pain or discomfort in your chest
when you walk at an ordinary pace on level
ground?
a. Yes
b. No
Qn 3: What do you do if you get the pain or
discomfort when you are walking?
a. stop or slow down
b. carry on after taking a pain-relieving medicine
that dissolves in your mouth
c. carry on walking
Qn 4: If you stand still, what happens to the pain
or discomfort?
a. relieved
b. not relieved
Qn 5: Will you show me where you usually
experience the pain or discomfort?
a. (6 & 11), or (7 & 8).
Angina=
Option ‘a’ for question 1
OR
Option ‘a’ for question 2
OR
Option ‘a’ for both question 3 and
question 4.
OR
Option ‘a’ for question 5
Asthma Have you ever been diagnosed with
asthma?
Qn 1: Attacks of wheezing or whistling
breathing?
a. Yes
b. No
Qn 2: Attack of wheezing that came on after you
stopped exercising or some other physical
activity?
a. Yes
b. No
Asthma=
Option ‘a’ for Qn 1
OR
Option ‘a’ for all questions from
question 2 to question 5.
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Table 3 Algorithms used to ascertain presence of non-communicable diseases (Continued)
NCDs Self-reported diagnosis Physical measurement/Symptom-based
assessment
Algorithm for physical
measurement/symptom-based
assessment
Qn 3: A feeling of tightness in your chest?
a. Yes
b. No
Qn 4: Have you woken up with a feeling of
tightness in your chest in the morning or any
other time?
a. Yes
b. No
Qn 5: Have you had an attack of shortness of
breath that came on without obvious cause
when you were not exercising or doing some
physical work?
a. Yes
b. No
Chronic lung
disease
Have you ever been diagnosed with
chronic lung disease (emphysema,
bronchitis, COPD)?
Qn 1: During the last 12 months, have you
experienced any shortness of breath at rest?
(while awake)
a. Yes
b. No
Qn 2: During the last 12 months, have you
experienced any coughing or wheezing for ten
minutes or more at a time?
a. Yes
b. No
Qn 3: During the last 12 months, have you
experienced any coughing up sputum or phlegm
for most days of the month for at least 3
months?
a. Yes
b. No
Chronic lung disease=
Option ‘a’ for Qn 1
OR
Option ‘a’ for both question 2 and
question 3
Depression Have you ever been diagnosed with
depression?
Qn 1: During the last 12 months, have you had a
period lasting several days when you felt sad,
empty or depressed?
a. Yes
b. No
Qn 2: During the last 12 months, have you had a
period lasting several days when you lost interest
in most things you usually enjoy such as personal
relationships, work or hobbies/recreation?
a. Yes
b. No
Qn 3: During the last 12 months, have you had a
period lasting several days when you have been
feeling your energy decreased or that you are
tired all the time?
a. Yes
b. No
Qn 4: Was this period [of sadness/loss of interest/
low energy] for more than 2 weeks?
a. Yes
b. No
Qn 5: Was this period [of sadness/loss of interest/
low energy] most of the day, nearly every day?
a. Yes
b. No
Qn 6: During this period, did you lose your
appetite?
a. Yes
b. No
Qn 7: Did you notice any slowing down in your
thinking?
a. Yes
b. No
Qn 8: Did you notice any problems falling asleep?
a. Yes
Group A:
Score=1 if option ‘a’ to question 1
Score=1 if option ‘a’ question 2
Score=1 if option ‘a’ to question 3
Addition of score= score for Group
A
Group B:
Score=1 if option ‘a’ to either
question 8 or question 9
Score=1 if option ‘a’ to either
question 7 or question 10
Score=1 if option ‘a’ to either
question 11 or question 13
Score=1 if option ‘a’ to either
question 14 or question 15
Score=1 if option ‘a’ to either
question 17 or question 18
Addition of score= score for Group
B
Group C:
Score=1 if option ‘a’ to question 6
Group D:
Score=1 if option ‘a’ to question 12
Group E:
Score for Group B + Score for Group
C + Score for Group D
Group F:
Score=1 if option ‘a’ to question 4
Group G:
If Score for Group A ≥2, AND Score
for Group F is =1, add the score for
Score for Group A + Score for Group
E
Depression=
Score for Group G ≥4
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Table 3 Algorithms used to ascertain presence of non-communicable diseases (Continued)
NCDs Self-reported diagnosis Physical measurement/Symptom-based
assessment
Algorithm for physical
measurement/symptom-based
assessment
b. No
Qn 9: Did you notice any problems waking up
too early?
a. Yes
b. No
Qn 10: During this period, did you have any
difficulties concentrating: for example, listening to
others, working, watching TV, listening to the
radio?
a. Yes
b. No
Qn 11: Did you notice any slowing down in your
moving around?
a. Yes
b. No
Qn 12: During this period, did you feel anxious
and worried most days?
a. Yes
b. No
Qn 13: During this period, were you so restless or
jittery nearly every day that you paced up and
down and couldn’t sit still?
a. Yes
b. No
Qn 14: During this period, did you feel negative
about yourself or like you had lost confidence?
a. Yes
b. No
Qn 15: Did you frequently feel hopeless- that
there was no way to improve things?
a. Yes
b. No
Qn 16: During this period, did your interest in sex
decrease?
a. Yes
b. No
Qn 17: Did you think of death, or wish you were
dead?
a. Yes
b. No
Qn 18: During this period, did you ever try to
end your life?
a. Yes
b. No
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Table 4 Definitions of prevalence of each chronic condition being undiagnosed, untreated, and uncontrolled
Non-
communicable
disease
Prevalence
Undiagnoseda Untreated Uncontrolled
unT-last 2 weeksb
(untreated in the last 2
weeks)
unT-last 12 monthsb
(untreated in last 12
months)
unC-T-last 2 weeksb
(treated in the last 2
weeks, and uncontrolled)
unC-T-last 12 monthsb
(treated in the last 12
months, and
uncontrolled)
Hypertension All subjects who self-
reported not being
diagnosed with
hypertension, but have
hypertension based on
symptom-based
assessment.
All subjects who self-
reported being diag-
nosed with hyperten-
sion, but self-reported
not taking treatment in
the last 2 weeks.
Treatment that they self-
reported taking include
medications or other
treatment such as a
weight loss program or
changing eating habits.
All subjects who self-
reported being diag-
nosed with hyperten-
sion, but self-reported
not taking treatment in
the last 12 months.
Treatment that they
self-reported taking in-
clude medications or
other treatment such as
a weight loss program
or changing eating
habits.
All subjects who are self-
reported taking treat-
ment for hypertension in
the last 2 weeks, but
have hypertension based
on BP measurement.
All subjects who are
self-reported taking
treatment for hyperten-
sion in the last 12
months, but have hyper-
tension based on BP
measurement
Angina All subjects who self-
reported not being
diagnosed with angina,
but have angina based
on symptom-based
assessment.
All subjects who self-
reported being diag-
nosed with angina, but
self-reported not taking
treated in the last 2
weeks.
Treatment that they self-
reported taking include
medications or other
treatment.
All subjects who self-
reported being diag-
nosed with angina, but
self-reported not taking
treatment in the last 12
months.
Treatment that they
self-reported taking in-
clude medications or
other treatment.
All subjects who self-
reported taking treat-
ment for angina in the
last 2 weeks, but have
angina based on
symptom-based
assessment.
All subjects who self-
reported taking treat-
ment for angina in the
last 12 months, but have
angina based on
symptom-based
assessment.
Arthritis All subjects who self-
reported not being
diagnosed with arthritis,
but have arthritis based
on symptom-based
assessment.
All subjects who self-
reported being diag-
nosed with arthritis, but
self-reported not taking
treatment in the last 2
weeks.
Treatment that they self-
reported taking include
medications or other
treatment.
All subjects who self-
reported being diag-
nosed with arthritis, but
self-reported not taking
treatment in the last 12
months.
Treatment that they
self-reported taking in-
clude medications or
other treatment.
All subjects who self-
reported taking treat-
ment for arthritis in the
last 2 weeks, but have
arthritis based on
symptom-based
assessment.
All subjects who self-
reported taking treat-
ment for arthritis in the
last 12 months, but have
arthritis based on
symptom-based
assessment.
Asthma All subjects who self-
reported not being
diagnosed with asthma,
but have asthma based
on symptom-based
assessment.
All subjects who self-
reported being diag-
nosed with asthma, but
self-reported not taking
treatment in the last 2
weeks.
Treatment that they self-
reported taking include
medications or other
treatment.
All subjects who self-
reported being diag-
nosed with asthma, but
self-reported not taking
treatment in the last 12
months.
Treatment that they
self-reported taking in-
clude medications or
other treatment.
All subjects who self-
reported taking treat-
ment for asthma in the
last 2 weeks, but have
asthma based on
symptom-based
assessment.
All subjects who self-
reported taking treat-
ment for asthma in the
last 12 months, but have
asthma based on
symptom-based
assessment.
Chronic Lung
Disease
All subjects who self-
reported not being
diagnosed with chronic
lung disease, but have
chronic lung disease
based on symptom-
based assessment.
All subjects who self-
reported being diag-
nosed with chronic lung
disease, but self-
reported not taking
treatment in the last 2
weeks.
Treatment that they self-
reported taking include
medications or other
treatment (like oxygen).
All subjects who self-
reported being diag-
nosed with chronic
lung disease, but self-
reported not taking
treatment in the last 12
months.
Treatment that they
self-reported taking in-
clude medications or
other treatment (like
oxygen).
All subjects who self-
reported taking treat-
ment for chronic lung
disease in the last 2
weeks, but have chronic
lung disease based on
symptom-based
assessment.
All subjects who self-
reported taking treat-
ment for chronic lung
disease in the last 12
months, but have
chronic lung disease
based on symptom-
based assessment.
Diabetes Not applicable (Diabetes
has no symptom-based
assessment)
All subjects who self-
reported being diag-
nosed with diabetes, but
self-reported not taking
All subjects who self-
reported being diag-
nosed with diabetes,
but self-reported not
Not applicable (Diabetes
has no symptom-based
assessment)
Not applicable (Diabetes
has no symptom-based
assessment)
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Table 4 Definitions of prevalence of each chronic condition being undiagnosed, untreated, and uncontrolled (Continued)
Non-
communicable
disease
Prevalence
Undiagnoseda Untreated Uncontrolled
unT-last 2 weeksb
(untreated in the last 2
weeks)
unT-last 12 monthsb
(untreated in last 12
months)
unC-T-last 2 weeksb
(treated in the last 2
weeks, and uncontrolled)
unC-T-last 12 monthsb
(treated in the last 12
months, and
uncontrolled)
treatment in the last 2
weeks.
Treatment that they self-
reported taking include
insulin or other blood
sugar lowering medica-
tions, special diet, exer-
cise regime, or weight
control program, as rec-
ommended by a health
professional.
taking treatment in the
last 12 months.
Treatment that they
self-reported taking in-
clude insulin or other
blood sugar lowering
medications only.
Cataract Not applicable (Cataract
has no symptom-based
assessment)
Not applicable (Subjects
self-reported not being
treated in the last 5
years, not in the last 2
weeks)
All subjects who self-
reported being diag-
nosed with cataract, but
self-reported not taking
treatment in the last 5
years.
Treatment refers to eye
surgery.
Not applicable (Cataract
has no symptom-based
assessment)
Not applicable (Cataract
has no symptom-based
assessment)
Depression All subjects who self-
reported not being
diagnosed with
depression, but have
depression based on
symptom-based
assessment.
All subjects who self-
reported being diag-
nosed with depression,
but self-reported not
taking treatment in the
last 2 weeks.
Treatment that they self-
reported taking include
medications or other
treatment. Other treat-
ment can include at-
tending therapy or
counselling sessions.
All subjects who self-
reported being diag-
nosed with depression,
but self-reported not
taking treatment in the
last 12 months.
Treatment that they
self-reported taking in-
clude medications or
other treatment. Other
treatment can include
attending therapy or
counselling sessions.
All subjects who self-
reported taking treat-
ment for depression in
the last 2 weeks, but has
depression based on
symptom-based
assessment.
All subjects who self-
reported taking treat-
ment for depression in
the last 12 months, but
has depression based
on symptom-based
assessment.
Stroke Not applicable (Stroke
has no symptom-based
assessment)
All subjects who self-
reported being diag-
nosed with stroke, but
self-reported not taking
treatment in the last 2
weeks.
Treatment that they self-
reported taking include
to medications or other
treatment.
All subjects who self-
reported being diag-
nosed with stroke, but
self-reported not taking
treatment in the last 12
months.
Treatment that they
self-reported taking in-
clude medications or
other treatment.
Not applicable (Stroke
has no symptom-based
assessment)
Not applicable (Stroke
has no symptom-based
assessment)
aRegarding self-reporting diagnoses, we defined respondents as self-reporting a non-communicable disease if they answered affirmatively to: “Have you ever been
diagnosed with…?”
bAll subjects who self-reported taking medication or other treatment are a perfect subset of those who self-reported being diagnosed, because the questionnaire
only asks subjects if they are taking treatment, if they self-report affirmatively to being diagnosed
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Table 5 Prevalence of comorbidity for each non-communicable disease
Non-communicable disease
Hypertension Angina Arthritis Asthma Chronic Lung
Disease
Diabetes Cataract Depression Stroke
Prevalence of subjects
(%)
No comorbidity 38.77 19.59 44.80 34.11 34.87 29.25 32.39 39.68 22.48
1 comorbidity 29.42 30.54 25.91 24.93 27.98 23.52 25.71 24.45 30.06
2 comorbidities 17.21 24.54 15.83 15.70 12.46 18.87 20.14 20.79 21.04
3 comorbidities 7.48 14.10 6.37 12.36 12.46 15.27 13.33 5.93 12.16
4+
comorbidities
7.11 11.23 7.10 12.89 12.23 13.10 8.43 9.15 14.26
Table 6 Prevalence of undiagnosed subjects for each non-communicable disease, with increasing number of comorbidities
Undiagnosed non-communicable disease
Hypertension Angina Arthritis Asthma Chronic Lung Disease Depression
Prevalence of undiagnosed subjects (%) No comorbidy 72.25 78.55 48.67 55.51 50.82 71.52
1 comorbidity 46.34 60.82 41.76 56.76 50.92 69.04
2 comorbidities 30.61 44.95 33.04 54.28 55.44 54.98
3 comorbidities 20.53 32.84 24.48 46.58 48.29 67.12
4+ comorbidities 16.61 28.63 21.77 64.09 36.38 63.45
Table 7 Prevalence of undiagnosed subjects for each non-communicable disease (NCD), with diagnosed concordant NCDs only, dis-
cordant NCDs only, and depression only
Undiagnosed non-communicable disease
Hypertension Angina Arthritis Asthma Chronic Lung
Disease
Depression
Prevalence of undiagnosed
subjects (%)
Diagnosed with only concordant
NCDs
26.83 39.20 NA 50.75 42.34 NA
Diagnosed with only discordant
NCDs
34.44 48.74 35.63 52.05 48.16 64.92
Diagnosed with only depression 35.49 65.45 34.45 47.70 57.51 NA
Table 8 Prevalence of untreated subjects for each non-communicable disease, with increasing comorbidities. (untreated in the last
2 weeks)
Untreated non-communicable disease (in the last 2 weeks)
Hypertension Angina Arthritis Asthma Chronic Lung
Disease
Diabetes Depression Stroke
Prevalence of untreated subjects
(%)
No comorbidity 42.93 56.15 62.16 51.80 92.96 30.64 69.11 85.39
1 comorbidity 35.72 49.76 62.20 54.76 84.84 32.85 67.67 55.63
2 comorbidities 25.95 38.20 51.51 23.28 87.60 37.28 72.29 42.43
3 comorbidities 20.03 30.81 48.93 36.61 94.57 22.65 78.51 42.16
4+
comorbidities
25.08 18.97 44.50 51.68 96.37 50.40 74.33 54.05
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Table 9 Prevalence of untreated subjects for each non-communicable disease (NCD), for comorbidity with only concordant NCDs,
only discordant NCDs, and only depression. (untreated in the last 2 weeks)
Untreated non-communicable disease (NCD) (in the last 2 weeks)
Hypertension Angina Arthritis Asthma Chronic
Lung
Disease
Diabetes Depression Stroke
Prevalence of
untreated subjects
(%)
Comorbidity with
only concordant
NCDs
27.39 40.49 NA 59.47 89.09 31.46 (concordant with
hypertension, angina, and/or
stroke);
25.85 (concordant with
cataract)
NA 46.50
Comorbidity with
only discordant
NCDs
38.51 59.21 55.34 40.85 89.76 37.04 71.34 67.84
Comorbidity with
only depression
35.81 30.41 70.33 89.11 98.16 0.40 NA 88.85
Table 10 Prevalence of untreated subjects for each non-communicable disease, with increasing comorbidity. (untreated in the last
12 months)
Untreated non-communicable disease (NCD) (in the last 12 months)
Hypertension Angina Arthritis Asthma Chronic
Lung
Disease
Diabetes Cataract
(last 5
yrs)
Depression Stroke
Prevalence
of untreated
subjects (%)
Comorbidity
with only
concordant
NCDs
8.72 12.48 NA 43.09 79.17 19.64 (concordant with
hypertension, angina, and/or
stroke); 23.17 (concordant with
cataract)
61.96 NA 34.78
Comorbidity
with only
discordant
NCDs
19.16 30.68 28.96 28.98 84.70 24.81 65.05 63.81 63.21
Comorbidity
with only
depression
22.76 17.10 33.84 4.11 98.16 65.83 92.27 NA 92.66
Table 11 Prevalence of untreated subjects for each non-communicable disease (NCD), for comorbidity with only concordant NCDs,
only discordant NCDs, and only depression. (untreated in the last 12 months)
Untreated non-communicable disease (NCD) (in the last 12 months)
Hypertension Angina Arthritis Asthma Chronic Lung
Disease
Diabetes Cataract Depression Stroke
Prevalence of untreated
subjects (%)
0 comorbidity 25.02 33.34 35.15 20.07 84.14 24.82 55.71 63.12 81.46
1 comorbidity 16.19 18.49 31.88 33.20 78.11 21.84 62.71 72.19 48.85
2
comorbidities
10.94 14.45 28.91 20.02 82.69 29.41 62.43 59.68 28.21
3
comorbidities
8.67 11.64 28.02 29.22 90.08 13.12 50.26 52.32 8.14
4+
comorbidities
6.28 6.75 19.31 22..39 94.34 34.80 77.69 58.37 17.85
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Table 12 Prevalence of uncontrolled subjects for each non-communicable disease, with increasing comorbidity. (treated in the last
2 weeks)
Uncontrolled non-communicable disease (NCD) (treated in the last 2 weeks)
Hypertension Angina Arthritis Asthma Chronic Lung Disease Depression
Prevalence of uncontrolled
subjects (%)
0 comorbidity 65.41 78.87 70.99 82.22 74.00 68.94
1 comorbidity 70.45 76.22 71.85 86.14 92.13 14.40
2 comorbidities 76.95 83.27 83.68 60.91 80.63 49.12
3 comorbidities 75.60 89.95 90.27 95.53 93.60 44.55
4+ comorbidities 78.46 94.32 95.99 63.17 50.84 79.57
Table 13 Prevalence of uncontrolled subjects for each non-communicable disease (NCD), for comorbidity with only concordant
NCDs, only discordant NCDs, and only depression. (treated in the last 2 weeks)
Uncontrolled non-communicable disease (NCD) (treated in the last 2
weeks)
Hypertension Angina Arthritis Asthma Chronic Lung
Disease
Depression
Prevalence of uncontrolled
subjects (%)
Comorbidity with only concordant
NCDs
73.49 80.28 NA 84.71 99.99 NA
Comorbidity with only discordant
NCDs
70.43 75.87 81.81 66.33 81.08 36.99
Comorbidity with only depression 60.62 86.99 82.31 99.96 99.99 NA
Table 14 Prevalence of uncontrolled subjects for each non-communicable disease, with increasing comorbidity (treated in last 12
months)
Uncontrolled non-communicable disease (NCD) (treated in the last 12 months)
Hypertension Angina Arthritis Asthma Chronic Lung Disease Depression
Prevalence of uncontrolled subjects (%) 0 comorbidity 63.43 73.09 66.56 78.30 60.50 68.83
1 comorbidity 64.21 72.46 69.86 73.17 89.96 40.21
2 comorbidities 74.70 77.12 83.94 65.36 54.62 66.71
3 comorbidities 72.32 83.29 85.92 93.47 82.47 46.76
4+ comorbidities 67.49 90.97 81.42 86.88 52.97 77.41
Table 15 Prevalence of uncontrolled subjects for each non-communicable disease (NCD), for comorbidity with only concordant
NCDs, discordant NCDs, and depression. (treated in the last 12 months)
Uncontrolled non-communicable disease (NCD) (in last 12 months)
Hypertension Angina Arthritis Asthma Chronic Lung
Disease
Depression
Prevalence of uncontrolled
subjects (%)
Comorbidity with only concordant
NCDs
63.43 84.36 NA 86.93 84.48 NA
Comorbidity with only discordant
NCDs
67.35 63.19 77.46 65.13 72.96 57.77
Comorbidity with only depression 52.27 88.30 63.19 62.69 99.99 NA
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